Coagulation management in patients undergoing mechanical circulatory support

Best Practice and Research: Clinical Anaesthesiology

Volumn 26, Issue 2, 2012, Pages 179-198

  Görlinger, Klaus ^a   Bergmann, Lars ^a   Dirkmann, Daniel ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

bleeding; fibrinogen concentrate; haemostasis; heparin induced thrombocytopenia; impedance aggregometry; platelet function; point of care testing; prothrombin complex concentrate; thrombo embolic events; thromboelastometry; ventricular assist device; von Willebrand syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OMEGA 3 FATTY ACID; PHENPROCOUMON; PRASUGREL; PROSTACYCLIN; TICAGRELOR; TIROFIBAN; WARFARIN;

ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CONTINUOUS INFUSION; DRUG EFFICACY; HEART ASSIST DEVICE; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMPEDANCE; INTERNATIONAL NORMALIZED RATIO; MECHANICAL CIRCULATORY SUPPORT THERAPY; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRIORITY JOURNAL; RISK REDUCTION; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

EID: 84865234497     PISSN: 15216896     EISSN: 1532169X     Source Type: Journal    
DOI: 10.1016/j.bpa.2012.04.003     Document Type: Review

References (220)

1. A.J. Clegg, D.A. Scott, and E. Loveman The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation Health Technol Assess 9 45 2005 Nov 1 132 [iii-iv]
2. L. Sharples, M. Buxton, and N. Caine Evaluation of the ventricular assist device programme in the UK Health Technol Assess 10 48 2006 Nov 1 119 [iii-iv]
3. R. John, F. Kamdar, and K. Liao Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy Ann Thorac Surg 86 4 2008 Oct 1227 1234
4. S. Crow, R. John, and A. Boyle Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices J Thorac Cardiovasc Surg 137 1 2009 Jan 208 215
5. T. Krabatsch, M. Schweiger, and A. Stepanenko Technical possibilities and limitations of mechanical circulatory support Anasthesiol Intensivmed Notfallmed Schmerzther 46 6 2011 Jun 414 421
6. ® II continuous-flow left ventricular assist system Expert Rev Med Devices 8 1 2011 Jan 11 21
7. T. Drews, M. Jurmann, and W. Pasic Coagulation management and mechanical circulatory support: a comparison of different devices Z Herz Thorax Gefäßchir 20 1 2006 21 28
8. T. Drews, B. Stiller, and M. Hübler Coagulation management in pediatric mechanical circulatory support ASAIO J 53 5 2007 Sep-Oct 640 645
9. R. John, F. Kamdar, and K. Liao Low thromboembolic risk for patients with the Heartmate II left ventricular assist device J Thorac Cardiovasc Surg 136 5 2008 Nov 1318 1323
10. A.A. Pitsis, and A.N. Visouli Update on ventricular assist device management in the ICU Curr Opin Crit Care 14 5 2008 Oct 569 578
11. C. Schmid, D. Hammel, and M.C. Deng Ambulatory care of patients with left ventricular assist devices Circulation 100 19 Suppl. 1999 Nov 9 II224 II228
12. B. Cosmi, G. Palareti, and M. Moia Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study Thromb Res. 100 4 2000 Nov 15 279 286
13. A. Koster, M. Kukucka, and F. Bach Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban Anesthesiology 94 2 2001 Feb 245 251
14. L. Cho, K. Kottke-Marchant, and A.M. Lincoff Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations Am J Cardiol 91 9 2003 May 1 1110 1113
15. A. Koster, D. Chew, and M. Gründel Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass Anesth Analg 96 2 2003 Feb 383 386
16. S.A. Kozek-Langenecker, C.K. Spiss, and A. Michalek-Sauberer Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration Crit Care Med 31 3 2003 Mar 864 868
17. A. Chung, S.M. Wildhirt, and S. Wang Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study J Thorac Cardiovasc Surg 129 4 2005 Apr 782 790
18. M.L. Zucker, A. Koster, and J. Prats Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery J Extra Corpor Technol 37 4 2005 Dec 364 368
19. R.C. Carroll, J.J. Chavez, and J.W. Simmons Measurement of patients' bivalirudin plasma levels by a thromboelastograph ecarin clotting time assay: a comparison to a standard activated clotting time Anesth Analg 102 5 2006 May 1316 1319
20. S. El Rouby, M. Cohen, and A. Gonzales The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures J Thromb Thrombolysis 21 2 2006 Apr 137 145
21. O. Ghez, R. Liesner, and A. Karimova Subcutaneous low molecular weight heparin for management of anticoagulation in infants on excor ventricular assist device ASAIO J 52 6 2006 Nov-Dec 705 707
22. M.J. Hursting, J. Dubb, and C.N. Verme-Gibboney Argatroban anticoagulation in pediatric patients: a literature analysis J Pediatr Hematol Oncol 28 1 2006 Jan 4 10
23. M. Beiderlinden, T.A. Treschan, and K. Görlinger Argatroban anticoagulation in critically ill patients Ann Pharmacother 41 5 2007 May 749 754
24. M. Beiderlinden, T. Treschan, and K. Görlinger Argatroban in extracorporeal membrane oxygenation Artif Organs 31 6 2007 Jun 461 465
25. K. Görlinger, C. Jambor, and A.A. Hanke Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis Transfus Med Hemother 34 2007 396 411
26. A. Koster, Y. Weng, and W. Böttcher Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT Ann Thorac Surg 83 5 2007 May 1865 1867
27. B. Meuris, J. Arnout, and D. Vlasselaers Long-term management of an implantable left ventricular assist device using low molecular weight heparin and antiplatelet therapy: a possible alternative to oral anticoagulants Artif Organs 31 5 2007 May 402 419
28. K.A. Tanaka, F. Szlam, and H.Y. Sun Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin Anesth Analg 105 4 2007 Oct 933 939
29. K. Görlinger, C. Jambor, and D. Dirkmann Platelet function analysis with point-of-care methods Herz 33 4 2008 Jun 297 305
30. A. Koster, S. Buz, and T. Krabatsch Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system J Card Surg 23 4 2008 Jul-Aug 321 323
31. J.D. Marmur, M. Lakhani, and S. El Rouby A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory J Invasive Cardiol 20 9 2008 Sep 449 454
32. R.J. Molinaro, F. Szlam, and J.H. Levy Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin Anesthesiology 109 1 2008 Jul 160 161
33. L.E. Samuels, J. Kohout, and E. Casanova-Ghosh Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices Ann Thorac Surg 85 5 2008 May 1651 1655
34. S.E. Sandner, D. Zimpfer, and P. Zrunek Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation Artif Organs 32 10 2008 Oct 819 822
35. C. Sucker, R.B. Zotz, and K. Görlinger Rotational thromboelastometry for the bedside monitoring of recombinant hirudin Acta Anaesthesiol Scand 52 3 2008 Mar 358 362
36. M.D. Thomas, C. Wood, and M. Lovett Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban J Heart Lung Transplant 27 8 2008 Aug 925 927
37. A.M. van den Besselaar, E. Witteveen, and F.J. van der Meer Influence of haematocrit on international normalised ratio (INR) differences between a whole blood point-of-care coagulation monitor and reference prothrombin time in plasma Thromb Haemost 100 6 2008 Dec 1181 1184
38. A.A. Weber, M. Adamzik, and H.S. Bachmann Interdisciplinary study group - clinical pharmacology of haemostasis. Methods to evaluate the pharmacology of oral antiplatelet drugs Herz 33 4 2008 Jun 287 296
39. A.J. Boyle, S.D. Russell, and J.J. Teuteberg Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation J Heart Lung Transplant 28 9 2009 Sep 881 887
40. P. Toulon, Y. Ozier, and A. Ankri Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study Thromb Haemost 101 2 2009 Feb 394 401
41. A. Arcangeli, B. Rocca, and G. Salvatori Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter Thromb Res. 126 1 2010 Jul 24 31
42. G. Gajos, P. Rostoff, and A. Undas Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study J Am Coll Cardiol 55 16 2010 Apr 20 1671 1678
43. A.L. Kobsar, J. Koessler, and M.S. Rajkovic Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system Platelets 21 2 2010 112 116
44. J. Silvain, F. Beygui, and A. Ankri Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test J Am Coll Cardiol 55 7 2010 Feb 16 617 625
45. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 6 2010 Jun 1116 1127
46. H. Copeland, P.E. Nolan, and D. Covington A method for anticoagulation of children on mechanical circulatory support Artif Organs 35 11 2011 Nov 1018 1023
47. B.H. Freed, V. Jeevanandam, and N. Jolly Aortic root and valve thrombosis after implantation of a left ventricular assist device J Invasive Cardiol 23 4 2011 Apr E63 E65
48. 12 receptor inhibition Platelets 22 1 2011 19 25
49. V.L. Serebruany, M. Miller, and A.N. Pokov Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia Cardiology 118 3 2011 187 194
50. T. Mackling, T. Shah, and V. Dimas Management of single-ventricle patients with berlin heart EXCOR ventricular assist device: single-center experience Artif Organs 2012 Jan 12 10.1111/j.1525-1594.2011.01403.x [Epub ahead of print]
51. J. Stangier, and M. Feuring Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran Blood Coagul Fibrinolysis 23 2 2012 Mar 138 143
52. S.V. Pamboukian, J.A. Tallaj, and R.N. Brown Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol J Heart Lung Transplant 30 8 2011 Aug 879 887
53. N. Uriel, S.W. Pak, and U.P. Jorde Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation J Am Coll Cardiol 56 15 2010 Oct 5 1207 1213
54. D.R. Stern, J. Kazam, and P. Edwards Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD J Card Surg 25 3 2010 May 352 356
55. C. Heilmann, U. Geisen, and F. Beyersdorf Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients Eur J Cardiothorac Surg 40 6 2011 Dec 1328 1333
56. U. Geisen, C. Heilmann, and F. Beyersdorf Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease Eur J Cardiothorac Surg 33 4 2008 Apr 679 684
57. C. Heilmann, U. Geisen, and F. Beyersdorf Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart Thromb Haemost 103 5 2010 May 962 967
58. C. Heilmann, U. Geisen, and F. Beyersdorf Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS) Intensive Care Med 38 1 2012 Jan 62 68
59. A.L. Meyer, D. Malehsa, and C. Bara Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device Circ Heart Fail. 3 6 2010 Nov 675 681
60. J.E. Sadler Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura Blood 112 1 2008 Jul 1 11 18
61. J.E. Sadler Aortic stenosis, von Willebrand factor, and bleeding N Engl J Med 349 4 2003 Jul 24 323 325
62. A. Vincentelli, S. Susen, and T. Le Tourneau Acquired von Willebrand syndrome in aortic stenosis N Engl J Med 349 4 2003 Jul 24 343 349
63. S. Panzer, R. Badr Eslam, and A. Schneller Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis Thromb Haemost 103 2 2010 Feb 408 414
64. J.L. Blackshear, H.V. Schaff, and S.R. Ommen Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy Mayo Clin Proc. 86 3 2011 Mar 219 224
65. M.W. Massyn, and S.A. Khan Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis Age Ageing 38 3 2009 May 267 270
66. H.J. Metzner, P. Hermentin, and T. Cuesta-Linker Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis Haemophilia 4 Suppl. 3 1998 25 32
67. G. Auerswald, and W. Kreuz Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience Haemophilia Suppl. 5 2008 Nov 14 39 46
68. W.L. Nichols, M.B. Hultin, and A.H. James von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) Haemophilia 14 2 2008 Mar 171 232
69. C.F. Weber, A.C. Schneider, and T. Kirschning Therapeutic options for perioperatively acquired platelet dysfunctions Anaesthesist 58 9 2009 Sep 931 940
70. C.F. Weber, W. Dietrich, and M. Spannagl A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery Anesth Analg 110 3 2010 Mar 1 702 707
71. C.F. Weber, K. Görlinger, and C. Byhahn Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy Eur J Anaesthesiol 28 1 2011 Jan 57 62
72. S. Lison, W. Dietrich, and M. Spannagl Review article: unexpected bleeding in the operating room: the role of acquired von Willebrand disease Anesth Analg 114 1 2012 Jan 73 81
73. L. Ternström, V. Radulovic, and M. Karlsson Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study Thromb Res 126 2 2010 Aug e128 e133
74. O. Gödje, U. Gallmeier, and M. Schelian Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation Thorac Cardiovasc Surg 54 1 2006 Feb 26 33
75. W.C. Korte, C. Szadkowski, and A. Gähler Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding Anesthesiology 110 2 2009 Feb 239 245
76. W.F. Korte XIII in perioperative coagulation management Best Pract Res Clin Anaesthesiol 24 1 2010 Mar 85 93
77. D.R. Spahn, and L.M. Asmis Excessive perioperative bleeding: are fibrin monomers and factor XIII the missing link? Anesthesiology 110 2 2009 Feb 212 213
78. K. Görlinger Coagulation management during liver transplantation Hämostaseologie 26 3 Suppl. 1 2006 Aug S64 S76
79. C.F. Weber, C. Jambor, and M. Marquardt Thromboelastometric detection of factor XIII deficiency Anaesthesist 57 5 2008 May 487 490
80. O.M. Theusinger, W. Baulig, and L.M. Asmis In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM) Thromb Haemost 104 2 2010 Aug 385 391
81. D. Dirkmann, K. Görlinger, and C. Gisbertz Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood Anesth Analg 114 6 2012 Jun 1182 1188
82. T. Yomo, D.L. Serna, and L.L. Powell Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation Artif Organs 24 5 2000 May 355 361
83. B.O. King, E.S. Whittow, and D.L. Serna Tirofiban administration attenuates platelet and platelet-neutrophil conjugation but not neutrophil degranulation during in vitro VAD circulation ASAIO J 47 3 2001 May-Jun 282 287
84. K. Zacharowski, C. Sucker, and P. Zacharowski Thromboelastography for the monitoring of lipopolysaccharide induced activation of coagulation Thromb Haemost 95 3 2006 Mar 557 561
85. T.A. Snyder, K.N. Litwak, and H. Tsukui Leukocyte-platelet aggregates and monocyte tissue factor expression in bovines implanted with ventricular assist devices Artif Organs 31 2 2007 Feb 126 131
86. M. Hartmann, S. Ozlügedik, and J. Peters Thiopental inhibits lipopolysaccharide-induced tissue factor expression Anesth Analg 109 1 2009 Jul 109 113
87. F. Semeraro, C.T. Ammollo, and N. Semeraro Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins Haematologica 94 6 2009 Jun 819 826
88. M. Adamzik, T. Langemeier, and U.H. Frey Comparison of thromboelastometry with simplified acute physiology score II and sequential organ failure assessment scores for the prediction of 30-day survival: a cohort study Shock 35 4 2011 Apr 339 342
89. H. Schöchl, C. Solomon, and A. Schulz Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia Mol Med 17 3-4 2011 Mar-Apr 266 272
90. C. Velik-Salchner, W. Streif, and P. Innerhofer Endotoxinemia-induced changes in coagulation as measured by rotation thromboelastometry technique and conventional laboratory tests: results of a pilot study on pigs Blood Coagul Fibrinolysis 20 1 2009 Jan 41 46
91. D. Fries, P. Innerhofer, and W. Streif Coagulation monitoring and management of anticoagulation during cardiac assist device support Ann Thorac Surg 76 5 2003 Nov 1593 1597
92. M.A. Studer, C.E. Kennedy, and W.J. Dreyer An alternative treatment strategy for pump thrombus in the DeBakey VAD Child: use of clopidogrel as a thrombolytic agent J Heart Lung Transplant 25 7 2006 Jul 857 861
93. D.L. Bhatt Intensifying platelet inhibition-navigating between Scylla and Charybdis N Engl J Med 357 20 2007 Nov 15 2078 2081
94. M. Attisani, P. Centofanti, and M. La Torre Safety and effectiveness of low dosing of double antiplatelet therapy during long-term left ventricular support with the INCOR system J Artif Organs 13 4 2010 Dec 202 206
95. D.J. McCrath, E. Cerboni, and R.J. Frumento Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction Anesth Analg 100 6 2005 Jun 1576 1583
96. T.T. Niemi, S.I. Kukkonen, and P.T. Hämmäinen Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist Perfusion 23 2 2008 Mar 107 110
97. J.L. Kashuk, E.E. Moore, and A. Sabel Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients Surgery 146 4 2009 Oct 764 772
98. H. Leemann, T. Lustenberger, and P. Talving The role of rotation thromboelastometry in early prediction of massive transfusion J Trauma 69 6 2010 Dec 1403 1408
99. R. Davenport, J. Manson, and H. De'Ath Functional definition and characterization of acute traumatic coagulopathy Crit Care Med 39 12 2011 Dec 2652 2658
100. K. Görlinger, D. Dirkmann, and A.A. Hanke First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study Anesthesiology 115 6 2011 Dec 1179 1191
101. H. Schöchl, B. Cotton, and K. Inaba FIBTEM provides early prediction of massive transfusion in trauma Crit Care 15 6 2011 Nov 11 R265 [Epub ahead of print]
102. M. Pezold, E.E. Moore, and M. Wohlauer Viscoelastic clot strength predicts coagulation-related mortality within 15 minutes Surgery 151 1 2012 Jan 48 54
103. M. Gerlach, B. Föhre, and D. Keh Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients Int J Artif Organs 20 1 1997 Jan 29 36
104. F. Majeed, W.J. Kop, and R.S. Poston Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices Nat Clin Pract Cardiovasc Med 6 2 2009 Feb 147 157
105. M. Adamzik, M. Eggmann, and U.H. Frey Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults Crit Care 14 5 2010 R178
106. F. Burzotta, L. Iacoviello, and A. Di Castelnuovo 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study J Thromb Thrombolysis 16 3 2003 Dec 149 154
107. J.L. Iribarren, J.J. Jimenez, and D. Hernández Postoperative bleeding in cardiac surgery: the role of tranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 gene Anesthesiology 108 4 2008 Apr 596 602
108. G. Sirgo, P. Morales, and J. Rello PAI-1 gene: pharmacogenetic association of 4G/4G genotype with bleeding after cardiac surgery - pilot study Eur J Anaesthesiol 26 5 2009 May 404 411
109. M. Adamzik, U.H. Frey, and K. Rieman Insertion/deletion polymorphism in the promoter of NF-κB1 influences severity but not mortality of acute respiratory distress syndrome Intensive Care Med 33 7 2007 Jul 1199 1203
110. M. Adamzik, U. Frey, and K. Riemann Der Insertions-Deletions polymorphismus NF-κB1 (-94ins/delATTG) im Promotor von NF-κB1 beeinflusst seine Expression sowie die LPS-induzierte Tuíssue-Factor- Aktivität Anästh Intensivmed 49 7/8 2008 Jul/Aug 365
111. A.J. Grau, S. Reiners, and C. Lichy Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study Stroke 34 4 2003 Apr 849 854
112. P.A. Gum, K. Kottke-Marchant, and P.A. Welsh A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 6 2003 Mar 19 961 965
113. E.J. Topol, P. Gum, and K. Kottke-Marchant Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 42 7 2003 Oct 1 1336 1337
114. T. Lang, and M. von Depka Possibilities and limitations of thromboelastometry/-graphy Hämostaseologie 26 3 Suppl. 1 2006 Aug S20 S29
115. S. Müller-Schunk, J. Linn, and N. Peters Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting AJNR Am J Neuroradiol 29 4 2008 Apr 786 791
116. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 8 2008 Apr 992 1000
117. D. Sibbing, S. Braun, and S. Jawansky Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 1 2008 Jan 121 126
118. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 10 2009 Mar 10 849 856
119. D. Aradi, A. Komócsi, and A. Vorobcsuk Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis Am Heart J 160 3 2010 Sep 543 551
120. D. Sibbing, T. Morath, and S. Braun Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting Thromb Haemost 103 1 2010 Jan 151 159
121. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2 2010 Feb 250 256 [Epub 2009 Nov 28]
122. D. Sibbing, S.R. Steinhubl, and S. Schulz Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 4 2010 Jul 20 317 318
123. J.M. Siller-Matula, G. Christ, and I.M. Lang Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay J Thromb Haemost 8 2 2010 Feb 351 359
124. N. von Beckerath, D. Sibbing, and S. Jawansky Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry Blood Coagul Fibrinolysis 21 1 2010 Jan 46 52
125. S.S. Brar, J. ten Berg, and R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 19 2011 Nov 1 1945 1954
126. G. Patti, V. Pasceri, and V. Vizzi Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study) Am J Cardiol 107 7 2011 Apr 1 995 1000
127. M.J. Price, D.J. Angiolillo, and P.S. Teirstein Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial Circulation 124 10 2011 Sep 6 1132 1137
128. D. Hazarbasanov, V. Velchev, and B. Finkov Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention J Thromb Thrombolysis 2012 Jan 15 [Epub ahead of print]
129. E. Mahmud, J.J. Cavendish, and S. Tsimikas Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention J Am Coll Cardiol 49 22 2007 Jun 5 2163 2171
130. L. Ang, V. Palakodeti, and A. Khalid Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel J Am Coll Cardiol 52 13 2008 Sep 23 1052 1059
131. B. Gaborit, C. Frre, and T. Cuisset Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control J Thromb Haemost 7 11 2009 Nov 1939 1941
132. I. Bernlochner, S. Steinhubl, and S. Braun Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment Thromb Haemost 104 6 2010 Dec 1193 1200
133. L.A. Malek, B. Kisiel, and M. Spiewak Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel Circ J 72 7 2008 Jul 1165 1169
134. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 4 2009 Jan 22 354 362
135. T. Simon, C. Verstuyft, and M. Mary-Krause French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 4 2009 Jan 22 363 375
136. D. Sibbing, T. Morath, and J. Stegherr Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 4 2009 Apr 714 719
137. H.J. Bouman, J.W. van Werkum, and G. Rudez The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor Thromb Haemost 103 2 2010 Feb 379 386
138. S.L. Close Clopidogrel pharmacogenetics: metabolism and drug interactions Drug Metabol Drug Interact 26 2 2011 45 51
139. H. Fernando, A.M. Dart, and K. Peter Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy Thromb Haemost 105 6 2011 Jun 933 944
140. M.J. Price, U.S. Tantry, and P.A. Gurbel The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors Rev Cardiovasc Med 12 1 2011 1 12
141. B.T. Ivandic, P. Schlick, and P. Staritz Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor Clin Chem 52 3 2006 Mar 383 388
142. W. Hochholzer, D. Trenk, and M.F. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 22 2010 Jun 1 2427 2434
143. J.M. Siller-Matula, G. Delle-Karth, and I.M. Lang Phenotyping versus genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study J Thromb Haemost 10 4 2012 Apr 529 542
144. K. Seibel, P. Berdat, and C. Boillat Hemostasis management in pediatric mechanical circulatory support Ann Thorac Surg 85 4 2008 Apr 1453 1456
145. A.A. Hanke, K. Roberg, and E. Monaca Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate) Eur J Med Res. 15 5 2010 May 18 214 219
146. M. Würtz, A.M. Hvas, and S.D. Kristensen Platelet aggregation is dependent on platelet count in patients with coronary artery disease Thromb Res 129 1 2012 Jan 56 61
147. U.T. Seyfert, H. Haubelt, and A. Vogt Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals Platelets 18 3 2007 May 199 206
148. L. Bochsen, P.I. Johansson, and A.T. Kristensen The influence of platelets, plasma and red blood cells on functional haemostatic assays Blood Coagul Fibrinolysis 22 3 2011 Apr 167 175
149. P. Diehl, C. Olivier, and C. Halscheid Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes Basic Res Cardiol 105 3 2010 May 379 387
150. H. Matsubayashi, D.R. Fastenau, and J.A. McIntyre Changes in platelet activation associated with left ventricular assist system placement J Heart Lung Transplant 19 5 2000 May 462 468
151. N. Bonaros, M.R. Mueller, and A. Salat Extensive coagulation monitoring in patients after implantation of the MicroMed Debakey continuous flow axial pump ASAIO J 50 5 2004 Sep-Oct 424 431
152. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 14 2007 Apr 10 1505 1516
153. K. Görlinger, L. Bergmann, and H. Macek Anticoagulation monitoring with thromboelastometry (ROTEM) and impedance aggregometry (Multiplate) I a patient with an INCOR vertricular assist device Eur J Anaesth 26 Suppl. 45 2009 89
154. C.T. Chin, T.Y. Wang, and K.J. Anstrom Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research Am Heart J 162 5 2011 Nov 844 851
155. N. Zimmermann, M. Kurt, and A. Wenk Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur J Cardiothorac Surg 27 4 2005 Apr 606 610
156. J. Börgermann, A. Kanashnik, and M. Sossdorf Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery Platelets 21 8 2010 610 615
157. M. Petricevic, B. Biocina, and S. Konosic Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy Heart Vessels 2011 Dec 28 [Epub ahead of print]
158. F. Santilli, N. Vazzana, and R. Liani Platelet activation in obesity and metabolic syndrome Obes Rev 13 1 2012 Jan 27 42
159. J. Bach, I. Kammerer, and F. Isgro The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery Platelets 20 3 2009 May 150 157
160. G. Campo, L. Fileti, and M. Valgimigli Poor response to clopidogrel: current and future options for its management J Thromb Thrombolysis 30 3 2010 Oct 319 331
161. J.A. Jakubowski, C.D. Payne, and Y.G. Li The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration Thromb Haemost 99 2 2008 Feb 409 415
162. M. Valgimigli, G. Campo, N. de Cesare Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 25 2009 Jun 30 3215 3222
163. G. Campo, L. Fileti, N. de Cesare 3T/2R Investigators Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy J Am Coll Cardiol 56 18 2010 Oct 26 1447 1455
164. A. Koster, S. Huebler, and E. Potapov Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single-institution experience in 358 consecutive patients Ann Thorac Surg 83 1 2007 Jan 72 76
165. J.N. Schroder, M.A. Daneshmand, and N.R. Villamizar Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients Ann Thorac Surg 84 3 2007 Sep 841 845
166. J.T. Lutz, H.J. Exner, and A. Schannewitzky Patient with heparin-induced thrombocytopenia type II and implanted left ventricular assist device Anaesthesist 57 1 2008 Jan 49 52
167. M.E. Dolch, L. Frey, and R. Hatz Lung Transplant Group TM. Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin-induced thrombocytopenia Exp Clin Transplant 8 4 2010 Dec 329 332
168. U. Pollak, J. Yacobobich, and H. Tamary Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature J Extra Corpor Technol 43 1 2011 Mar 5 12
169. F.B. Taylor Jr., C.H. Toh, and W.K. Hoots Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Thromb Haemost 86 5 2001 Nov 1327 1330
170. S.C. Chevuru, M.C. Sola, D.W. Theriaque Florida Collaborative Neonatology Research Group Multicenter analysis of platelet transfusion usage among neonates on extracorporeal membrane oxygenation Pediatrics 109 6 2002 Jun e89
171. M. Levi, C.H. Toh, and J. Thachil Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology Br J Haematol 145 1 2009 Apr 24 33
172. A. Greinacher, and K. Selleng Thrombocytopenia in the intensive care unit patient Hematology Am Soc Hematol Educ Program 2010 2010 135 143
173. M. Thielmann, M. Bunschkowski, and P. Tossios Perioperative thrombocytopenia in cardiac surgical patients - incidence of heparin-induced thrombocytopenia, morbidities and mortality Eur J Cardiothorac Surg 37 6 2010 Jun 1391 1395
174. D.M. Vandijck, S.I. Blot, and J.J. De Waele Thrombocytopenia and outcome in critically ill patients with bloodstream infection Heart Lung 39 1 2010 Jan-Feb 21 26
175. T.E. Warkentin, A. Greinacher, A. Koster American College of Chest Physicians Treatment and prevention of heparin-induced thrombocytopenia: American college of chest physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 6 Suppl. 2008 Jun 340S 380S
176. A. Greinacher, K. Althaus, and K. Krauel Heparin-induced thrombocytopenia Hämostaseologie 30 1 2010 Jan 17 18 20-8
177. A. Koster, S. Sänger, and R. Hansen Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices ASAIO J 46 3 2000 May-Jun 319 322
178. P. Nocera, J.C. Thiranos, and A. Steib Heparin induced thrombocytopenia in patients with ventricular assistance device bridge-to-transplantation. A case series Minerva Cardioangiol 56 6 2008 Dec 697 701
179. T.E. Warkentin, A. Greinacher, and A. Koster Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg 87 5 2009 May 1633 1640
180. S. Selleng, B. Malowsky, and U. Strobel Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive J Thromb Haemost 8 1 2010 Jan 30 36
181. M.C. Morel-Kopp, M. Aboud, and C.W. Tan Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies Thromb Res 125 5 2010 May e234 e239
182. T.H. Kiser, R. Jung, and R. MacLaren Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia Pharmacotherapy 25 12 2005 Dec 1736 1745
183. M.J. Hursting, and J. Soffer Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia Drug Saf 32 3 2009 203 218
184. I. Apostolidou, M.F. Sweeney, and E. Missov Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia Anesth Analg 106 2 2008 Feb 404 408
185. M.J. Gandhi, R.A. Pierce, and L. Zhang Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant J Cardiothorac Surg 2 2007 Jul 6 32
186. B.A. Bruckner, D.J. DiBardino, and Q. Ning High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII J Heart Lung Transplant 28 8 2009 Aug 785 790
187. I.D. Gregoric, V. Patel, and R. Radovancevic Pulmonary microthrombi during left ventricular assist device implantation Tex Heart Inst J 32 2 2005 228 231
188. B.D. Spiess, D. Royston, and J.H. Levy Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes Transfusion 44 2004 1143 1148
189. S.I. Dara, R. Rana, and B. Afessa Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy Crit Care Med 33 2005 2667 2671
190. M. Raghavan, and P.E. Marik Anemia, allogenic blood transfusion, and immunomodulation in the critically ill Chest 127 2005 295 307
191. M.K. Banbury, M.E. Brizzio, and J. Rajeswaran Transfusion increases the risk of postoperative infection after cardiovascular surgery J Am Coll Surg 202 2006 131 138
192. H. Khan, J. Belsher, and M. Yilmaz Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients Chest 131 2007 1308 1314
193. G.J. Murphy, B.C. Reeves, and C.A. Rogers Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery Circulation 116 2007 2544 2552
194. P.E. Marik, and H.L. Corwin Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature Crit Care Med 36 2008 2667 2674
195. S.J. Stanworth The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy Hematology Am Soc Hematol Educ Program 2007 179 186
196. B. Sarani, W.J. Dunkman, and L. Dean Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection Crit Care Med 36 2008 1114 1118
197. A. Shanwell, T.M. Andersson, and K. Rostgaard Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma Vox Sang 96 2009 316 323
198. P. Renaudier, D. Rebibo, and C. Waller Pulmonary complications of transfusion (TACO-TRALI) Transfus Clin Biol 16 2009 218 232
199. A.A. Hanke, U. Herold, D. Dirkmann, K. Tsagakis, H. Jakob, and K. Görlinger Thromboelastometry based early goal-directed coagulation management reduces blood transfusion requirements, adverse events, and costs in acute type A aortic dissection: A pilot study Transfus Med Hemother 39 2 2012 Apr 121 128
200. K. Görlinger, D. Dirkmann, and C.F. Weber Algorithms for transfusion and coagulation management in massive haemorrhage Anästh Intensivemed 52 2 2011 145 159
201. K. Görlinger, D. Fries, D. Dirkmann, C.F. Weber, A.A. Hanke, and H. Schöchl Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy Transfus Med Hemother 39 2 2012 Apr 104 113
202. S.T. Hiippala, G.J. Myllylä, and E.M. Vahtera Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates Anesth Analg 81 2 1995 360 365
203. D. Bolliger, K. Görlinger, and K.A. Tanaka Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution Anesthesiology 113 2010 1205 1219
204. H.I. Ucar, M. Oc, and M. Tok Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery Heart Surg Forum 10 2007 E392 E396
205. M. Karlsson, L. Ternström, and M. Hyllner Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study Transfusion 48 2008 2152 2158
206. M. Reinhöfer, M. Brauer, and U. Franke The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass Blood Coagul Fibrinolysis 19 2008 212 219
207. M. Karlsson, L. Ternström, and M. Hyllner Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study Thromb Haemost 102 2009 137 144
208. N. Rahe-Meyer, M. Pichlmaier, and A. Haverich Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study Br J Anaesth 102 2009 785 792
209. N. Rahe-Meyer, C. Solomon, and M. Winterhalter Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery J Thorac Cardiovasc Surg 138 3 2009 694 702
210. S. Kozek-Langenecker, B. Sorensen, and J. Hess Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review Critical Care 15 2011 R239
211. H. Ostermann, S. Haertel, and S. Knaub Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers Thromb Haemost 98 2007 790 797
212. D. Bruce, and T.J.C. Nokes Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital Critical Care 12 2008 R105
213. I. Pabinger, B. Brenner, U. Kalina For the Beriplex P/N anticoagulation reversal study group Prothrombin complex concentrate (Beriplex-P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial J Thromb Haemost 6 2008 622 631
214. I. Pabinger-Fasching Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate Thromb Res 122 Suppl. 2 2008 S19 S22
215. ® P/N) J Thromb Haemost 7 Suppl. 2 2009 863
216. K.S. Schick, J.M. Fertmann, and K.W. Jauch Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding Crit Care 13 2009 R191
217. B. Sørensen, D.R. Spahn, and P. Innerhofer Clinical review: prothrombin complex concentrates - evaluation of safety and thrombogenicity Critical Care 15 2011 201
218. A. Majeed, A. Eelde, and A. gren Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy Thromb Res 129 2 2012 146 151
219. L. Holland, T.E. Warkentin, and M. Refaai Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose Transfusion 49 2009 1171 1177
220. U. Kalina, H. Bickhard, and S. Schulte Biochemical comparison of seven commercially available prothrombin complex concentrates Int J Clin Pract 62 2008 1614 1622